GSK’s new boss, Luke Miels, has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two late-stage medications.
The FTSE 100 company is increasing its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech company that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash.
One in five of the 1.92m patients on list wait longer than six weeks for tests such as CT and MRI scans, analysis shows
A record number of people are waiting for a diagnostic test on the NHS, triggering fears that delays in accessing CT and MRI scans could endanger patients’ health.
A total of 1.92 million patients in England are waiting to have a test to diagnose their illness such as by an ultrasound scan, assessment of their hearing, bone scan or various tests for cancer.
The diagnostic waiting list has grown by 500,000 since 2022.
It is 83% higher than beforethe Covid pandemic.
On current trends the waiting list will hit 2 million in March 2027.
A potential response to cancer is written — on a microscopic level — in its very tumor cells. For decades, treatment and prognosis of the disease has been largely determined by the organ, the anatomical location in which the cancerous mass is located. But now, science has placed a spotlight on something more ambitious: learning the tumor’s signature, or rather, the molecular alterations that characterize its malignant cells. The latest meeting of the American Society of Clinical Oncology (ASCO), which took place last weekend in Chicago, has given further impetus to precision oncology and highlighted how cancer biology, those microscopic genetic characteristics that define it, are playing an increasingly important role in determining therapeutic approach, and even predicting prognosis.
A groundbreaking cancer treatment hailed as one of the most promising advances in oncology is set to be tested in Portugal after delivering what experts described as “unprecedented” results in
A glance at Winette Van der Graaf’s extensive résumé is enough to certify that this Dutch oncologist has been an exceptional witness, if not a fundamental part, of the great scientific revolution that cancer research has undergone in recent decades. An expert in sarcomas and cancers in teens and young adults, Van der Graaf was one of the pioneers in providing care — and personalized assistance — to people between the ages of 15 and 39 who develop cancer. Sometimes in no man’s land, halfway between pediatric and adult oncology, cancer at this age puts life “on hold,” says Van der Graaf.
In 2021, Miriam González, a 35-year-old from Murcia, Spain, went to the doctor because she was bleeding from her breast. She was told to relax: everything was normal. But in 2024, she was diagnosed with breast cancer. And, shortly afterward, she discovered it was metastatic, at stage four.
Login
